RxDoctor Payments Data

Thomas Baudo, MD

Ophthalmology · Vero Beach, FLNPI 1205881976

Payments from drug & device makers

$2,293in general payments, 2019–2025

Across 93 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$582
  • AbbVie$571
  • Genentech USA, Inc.$371
  • Apellis Pharmaceuticals, Inc.$251
  • Astellas Pharma US Inc$145
  • Harrow Eye, LLC$95
  • plus $278 from 6 others

What the payments were for

  • Food & beverage$2,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,293 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$8,057,757
Medicare patients
1,995
Services billed
122,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$53,801
RhopressaNetarsudil Mesylate66$39,752
LumiganBimatoprost68$38,749
VyzultaLatanoprostene Bunod39$18,912
Latanoprost937$14,128
RocklatanNetarsudil Mesylat/Latanoprost31$9,836
Cyclosporine24$9,314
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat315$7,377
Brimonidine Tartrate225$6,346
Prednisolone Acetate118$5,855
Dorzolamide-TimololDorzolamide/Timolol/Pf42$5,164
Alphagan PBrimonidine Tartrate11$4,177
TafluprostTafluprost/Pf15$3,212
Timolol Maleate179$3,105
Brinzolamide17$3,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$571$96,727124 claims
Bausch & Lomb Americas Inc.Vyzulta$82$18,91239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →